In the present study, our results for the first time demonstrated that the lncRNA DUXAP9‐206, which is closely correlated with clinical NSCLC patient outcomes is a vitally important lncRNA that promoted the progression in NSCLC. This evidence concerns the gene DUXAP9 and non-small cell lung carcinoma.